These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

488 related articles for article (PubMed ID: 30578336)

  • 1. The epidemiology of idiopathic pulmonary fibrosis and interstitial lung diseases at risk of a progressive-fibrosing phenotype.
    Olson AL; Gifford AH; Inase N; Fernández Pérez ER; Suda T
    Eur Respir Rev; 2018 Dec; 27(150):. PubMed ID: 30578336
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence and Incidence of Chronic Fibrosing Interstitial Lung Diseases with a Progressive Phenotype in the United States Estimated in a Large Claims Database Analysis.
    Olson AL; Patnaik P; Hartmann N; Bohn RL; Garry EM; Wallace L
    Adv Ther; 2021 Jul; 38(7):4100-4114. PubMed ID: 34156606
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Epidemiology of fibrosing interstitial lung diseases in the department of Haute Garonne].
    Villeneuve T; Prévot G; Lintz F; Mourin G; Ferry G; Bousquet E; Perelroizen H; Boghanim T; Faviez G; Noël-Savina E; Collot S; Le Borgne A; Didier A
    Rev Mal Respir; 2021 Dec; 38(10):972-979. PubMed ID: 34629221
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Healthcare Resources Utilization and Costs of Patients with Non-IPF Progressive Fibrosing Interstitial Lung Disease Based on Insurance Claims in the USA.
    Olson AL; Maher TM; Acciai V; Mounir B; Quaresma M; Zouad-Lejour L; Wells CD; De Loureiro L
    Adv Ther; 2020 Jul; 37(7):3292-3298. PubMed ID: 32451950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progressive fibrosing interstitial lung diseases: current practice in diagnosis and management.
    Wijsenbeek M; Kreuter M; Olson A; Fischer A; Bendstrup E; Wells CD; Denton CP; Mounir B; Zouad-Lejour L; Quaresma M; Cottin V
    Curr Med Res Opin; 2019 Nov; 35(11):2015-2024. PubMed ID: 31328965
    [No Abstract]   [Full Text] [Related]  

  • 6. Possible value of antifibrotic drugs in patients with progressive fibrosing non-IPF interstitial lung diseases.
    Torrisi SE; Kahn N; Wälscher J; Sarmand N; Polke M; Lars K; Eichinger M; Heussel CP; Palmucci S; Sambataro FM; Sambataro G; Sambataro D; Vancheri C; Kreuter M
    BMC Pulm Med; 2019 Nov; 19(1):213. PubMed ID: 31718637
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic and Prognostic Biomarkers for Chronic Fibrosing Interstitial Lung Diseases With a Progressive Phenotype.
    Inoue Y; Kaner RJ; Guiot J; Maher TM; Tomassetti S; Moiseev S; Kuwana M; Brown KK
    Chest; 2020 Aug; 158(2):646-659. PubMed ID: 32268131
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nintedanib: A Review in Fibrotic Interstitial Lung Diseases.
    Lamb YN
    Drugs; 2021 Apr; 81(5):575-586. PubMed ID: 33765296
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological management of progressive-fibrosing interstitial lung diseases: a review of the current evidence.
    Richeldi L; Varone F; Bergna M; de Andrade J; Falk J; Hallowell R; Jouneau S; Kondoh Y; Morrow L; Randerath W; Strek M; Tabaj G
    Eur Respir Rev; 2018 Dec; 27(150):. PubMed ID: 30578333
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The natural history of progressive fibrosing interstitial lung diseases.
    Kolb M; Vašáková M
    Respir Res; 2019 Mar; 20(1):57. PubMed ID: 30871560
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence and prognosis of chronic fibrosing interstitial lung diseases with a progressive phenotype.
    Takei R; Brown KK; Yamano Y; Kataoka K; Yokoyama T; Matsuda T; Kimura T; Suzuki A; Furukawa T; Fukuoka J; Johkoh T; Goto Y; Kondoh Y
    Respirology; 2022 May; 27(5):333-340. PubMed ID: 35293077
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Presentation, diagnosis and clinical course of the spectrum of progressive-fibrosing interstitial lung diseases.
    Cottin V; Hirani NA; Hotchkin DL; Nambiar AM; Ogura T; Otaola M; Skowasch D; Park JS; Poonyagariyagorn HK; Wuyts W; Wells AU
    Eur Respir Rev; 2018 Dec; 27(150):. PubMed ID: 30578335
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estimation of the Prevalence of Progressive Fibrosing Interstitial Lung Diseases: Systematic Literature Review and Data from a Physician Survey.
    Olson A; Hartmann N; Patnaik P; Wallace L; Schlenker-Herceg R; Nasser M; Richeldi L; Hoffmann-Vold AM; Cottin V
    Adv Ther; 2021 Feb; 38(2):854-867. PubMed ID: 33315170
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Claims-based Prevalence of Disease Progression among Patients with Fibrosing Interstitial Lung Disease Other than Idiopathic Pulmonary Fibrosis in the United States.
    Singer D; Bengtson LGS; Conoscenti CS; Laouri M; Shetty SS; Anderson AJ; Brown KK
    Ann Am Thorac Soc; 2022 Jul; 19(7):1112-1121. PubMed ID: 35015982
    [No Abstract]   [Full Text] [Related]  

  • 15. Exposure-efficacy analyses of nintedanib in patients with chronic fibrosing interstitial lung disease.
    Schmid U; Weber B; Magnusson MO; Freiwald M
    Respir Med; 2021; 180():106369. PubMed ID: 33798871
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence and prognosis of unclassifiable interstitial lung disease.
    Ryerson CJ; Urbania TH; Richeldi L; Mooney JJ; Lee JS; Jones KD; Elicker BM; Koth LL; King TE; Wolters PJ; Collard HR
    Eur Respir J; 2013 Sep; 42(3):750-7. PubMed ID: 23222877
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute exacerbations of progressive-fibrosing interstitial lung diseases.
    Kolb M; Bondue B; Pesci A; Miyazaki Y; Song JW; Bhatt NY; Huggins JT; Oldham JM; Padilla ML; Roman J; Shapera S
    Eur Respir Rev; 2018 Dec; 27(150):. PubMed ID: 30578331
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Healthcare utilisation and costs in the diagnosis and treatment of progressive-fibrosing interstitial lung diseases.
    Holtze C; Flaherty K; Kreuter M; Luppi F; Moua T; Vancheri C; Scholand MB
    Eur Respir Rev; 2018 Dec; 27(150):. PubMed ID: 30578337
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Idiopathic pulmonary fibrosis-epidemiology, causes, and clinical course].
    Schäfer SC; Funke-Chambour M; Berezowska S
    Pathologe; 2020 Feb; 41(1):46-51. PubMed ID: 31993696
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapidly non-ipf progressive fibrosing interstitial lung disease: a phenotype with an ipf-like behavior.
    Khine N; Mudawi D; Rivera-Ortega P; Leonard C; Chaudhuri N; Margaritopoulos GA
    Sarcoidosis Vasc Diffuse Lung Dis; 2020; 37(2):231-233. PubMed ID: 33093788
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.